

| Inpatient & Outpatients Jan 2017- Dec 2018 Susceptibilities shown in % susceptible | Class↓ | Aminoglycosides (AMG) | | | Penicillins | | | Cephalosporins (generation) | Furanes | Glycopeptide | Lincosamide | Oxazolidinone | Fluoroquinolones | Tetracyclines | Sulfonamide |
|---|--------|-----------------------|--------------------|------------|---------------------------------|-----------|-----------------|-----------------------------|------------|--------------|-------------|---------------|------------------|---------------|-------------|
| | | Number of Organisms | Gentamicin synergy | Ampicillin | Benzylpenicillin (Penicillin G) | Oxacillin | Cefazolin (1st) | Nitrofurantoin | Vancomycin | Clindamycin | Linezolid | Levofloxacin | Tetracycline | SMX/TMP | |
| Susceptibility Breakpoints | | | ≤8 | * | ** | ≤8 | ≤32 | *** | **** | ***** | ≤2 | ≤4 | ≤40 | | |
| Approx. drug cost/day ‡ | | \$ | \$\$\$\$ | \$\$\$\$\$ | \$\$\$ | \$ | \$ | \$ | \$ | \$ | \$\$\$ | \$ | \$\$ | \$ | |
| <i>Enterococcus faecalis</i> | 381 | 68 | 98 | 98 | | 97 | 97 | | | 100 | | 24 | | | |
| <i>Enterococcus faecium!</i> | 28 | 67 | 21 | 21 | | 15 | 50 | | | 96 | 20 | 28 | | | |
| MRSA | 364 | | | | | | | 100 | 59 | | | 82 | 92 | | |
| MSSA | 533 | | | | 100 | 100 | | | 78 | | | 93 | 98 | | |
| Coag Neg Staphylococcus | 389 | | | | 55 | 56 | | | 99 | 59 | | 85 | 82 | | |
| <i>Streptococcus agalactiae</i> | 363 | | 100 | 99 | | 100 | | 100 | 42 | | 96 | | | | |
| <i>Streptococcus pneumoniae!</i> | 22 | | | 100 | | | | | 76 | | 95 | 77 | | | |

Using this Antibiogram:
This data represents susceptibility rates in this geographical area. Use this information to choose EMPIRIC therapy that has expected coverage against suspected bacteria.

Legend

SMX/TMP:
Trimethoprim/Sulfamethoxazole

PIP/TAZO: Piperacillin/Tazobactam

Black: Antibiotic is NOT expected to cover this bacteria, should NOT be used to treat this bacteria or was NOT tested

!: Interpret with caution due to low organism count

7 E.coli and 29 Klebsiella isolates were ESBL+

‡: hospital cost based on severe disease in 70kg patient without renal impairment or monitoring

\$: 0.01-19.99
 \$\$: \$20 - \$49.99 per day
 \$\$\$: \$50 - \$74.99 per day
 \$\$\$\$: \$75 - \$99.99 per day
 \$\$\$\$: \$100 - \$250 per day

| Inpatient & Outpatients Jan 2017- Dec 2018 Susceptibilities shown in % susceptible | Class↓ | Aminoglycosides (AMG) | | | Penicillins | | | Cephalosporins (generation) | | | | Carbapenems | Furanes | Fluoroquinolones | | Sulfonamide |
|---|--------|-----------------------|----------|------------|-------------|------------|----------------------|-----------------------------|-----------------|-----------------|-------------------|----------------|-----------|------------------|---------------|--------------|
| | | Number of Organisms | Amikacin | Gentamicin | Tobramycin | Ampicillin | Ampicillin/ Subactam | Pip/Tazo | Cefazolin (1st) | Cefoxitin (2nd) | Ceftriaxone (3rd) | Cefepime (4th) | Meropenem | Nitrofurantoin | Ciprofloxacin | Levofloxacin |
| Susceptibility Breakpoints | | ≤16 | ≤4 | ≤4 | ≤8 | ≤8 | ***** | ≤8 | ≤8 | ≤8 | ≤8 | ≤4 | ≤32 | ≤1 | ≤2 | ≤40 |
| Approx. drug cost/day‡ | | \$ | \$ | \$ | \$\$\$\$ | \$\$ | \$\$ | \$ | \$\$ | \$ | \$\$ | \$\$ | \$ | \$ | \$ | \$ |
| <i>Citrobacter koseri</i> | 36 | | 100 | | | | 100 | | | | | 100 | | 97 | 97 | 97 |
| <i>Citrobacter freundii</i> | 96 | | 90 | | | | 83 | | | | | 97 | 86 | 86 | 86 | 80 |
| <i>Enterobacter aerogenes</i> | 62 | | 100 | | | | 88 | | | | | 100 | 20 | 100 | 100 | 98 |
| <i>Enterobacter cloacae complex</i> | 172 | | 95 | | | | 88 | | | | | 98 | 25 | 94 | 95 | 84 |
| <i>Escherichia coli</i> | 2933 | 97 | 92 | 24 | 54 | 61 | 97 | 88 | 88 | 94 | | 99 | 96 | 80 | 80 | 78 |
| <i>Klebsiella pneumoniae</i> | 595 | | 96 | | | 85 | 97 | 91 | 95 | 95 | | 99 | | 94 | 94 | 90 |
| <i>Klebsiella oxytoca</i> | 142 | | 97 | | | 65 | 95 | 61 | 97 | 98 | | 100 | 81 | 96 | 96 | 95 |
| <i>Morganella morganii</i> | 47 | | 78 | | | | 95 | | | | | 95 | | 68 | 71 | 60 |
| <i>Proteus mirabilis</i> | 402 | 97 | 88 | 22 | 63 | 73 | 93 | 76 | 79 | 85 | | 93 | | 54 | 55 | 67 |
| <i>Pseudomonas aeruginosa</i> | 295 | | 91 | 77 | | | 99 | | | | | | 94 | 95 | 82 | 77 |
| <i>Serratia marcescens</i> | 51 | | 100 | | | | | | | | | 94 | | 98 | 98 | 100 |
| <i>Stenotrophomonas maltophilia</i> | 34 | | | | | | | | | | | | | 67 | | 73 |

*: S. pneumo meningitis: ≤ 0.0625, pneumonia: ≤ 2, Other: ≤ 0.125
 **: ≤ 0.25 except Staph ≤ 2
 ***: S. aureus ≤ 2, Strep ≤ 1, Other ≤ 4
 ****: Staph ≤ 0.5, Strep ≤ 0.25
 *****: Staph ≤ 4, Other ≤ 2
 *****: ≤ 16 except Pseudo ≤ 64